Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD

Journal of the American Society of Nephrology

Volumn 26, Issue 8, 2015, Pages 1787-1794

  Mishima, Eikan ^a,b   Fukuda, Shinji ^c,d   Shima, Hisato ^a   Hirayama, Akiyoshi ^c   Akiyama, Yasutoshi ^a,b   Takeuchi, Yoichi ^a   Fukuda, Noriko N ^c   Suzuki, Takehiro ^a   Suzuki, Chitose ^a   Yuri, Akinori ^e   Kikuchi, Koichi ^b   Tomioka, Yoshihisa ^e   Ito, Sadayoshi ^a   Soga, Tomoyoshi ^c   Abe, Takaaki ^a,b,e  

^a Endocrinology Department   (United States)

^b TOHOKU UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d RIKEN Center for Integrative Medical Sciences   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITIC ACID; ADENINE; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; COLLAGEN TYPE 3; COLLAGEN TYPE 3A1; HIPPURIC ACID; INDICAN; INTERLEUKIN 6; LUBIPROSTONE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTECTIVE AGENT; RNA 16S; SODIUM; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CHLORIDE CHANNEL STIMULATING AGENT; PROSTAGLANDIN E1;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY DISEASE; CLOSTRIDIA; CLOSTRIDIUM; COLON FLORA; CONTROLLED STUDY; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; LACTOBACILLACEAE; LACTOBACILLUS; LAMINA PROPRIA; MALE; MASS SPECTROMETRY; MICROBIAL DIVERSITY; MOUSE; NONHUMAN; PARABACTEROIDES; PH; POLYMERASE CHAIN REACTION; POLYURIA; PREVOTELLA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RENAL PROTECTION; SODIUM BLOOD LEVEL; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; GASTROINTESTINAL TRACT; KIDNEY FAILURE, CHRONIC; MICROBIOLOGY; MICROFLORA; PRECLINICAL STUDY; RANDOMIZATION; UREMIA;

ADENINE; ALPROSTADIL; ANIMALS; CHLORIDE CHANNEL AGONISTS; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL TRACT; KIDNEY FAILURE, CHRONIC; LUBIPROSTONE; MALE; MICE, INBRED C57BL; MICROBIOTA; RANDOM ALLOCATION; UREMIA;

EID: 84938928604     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014060530     Document Type: Article

References (34)

1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW: Chronic kidney disease: Global dimension and perspectives. Lancet 382: 260-272, 2013
2. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J; European Uremic Toxin Work Group: A bench to bedside view of uremic toxins. J Am Soc Nephrol 19: 863-870, 2008
3. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S: The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers in-doxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 62: S23-S28, 1997
4. Tremaroli V, Bäckhed F: Functional interactions between the gut microbiota and host metabolism. Nature 489: 242-249, 2012
5. Fukuda S, Ohno H: Gut microbiome and metabolic diseases. Semin Immunopathol 36: 103-114, 2014
6. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL: Chronic kidney disease alters intestinal microbial flora. Kidney Int 83: 308-315, 2013
7. Ramezani A, Raj DS: The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 25: 657-670, 2014
8. Meyer TW, Hostetter TH: Uremic solutes from colon microbes. Kidney Int 81: 949-954, 2012
9. Lacy BE, Levy LC: Lubiprostone: A chloride channel activator. J Clin Gastroenterol 41: 345-351, 2007
10. Fei G, Wang YZ, Liu S, Hu HZ, Wang GD, Qu MH, Wang XY, Xia Y, Sun X, Bohn LM, Cooke HJ, Wood JD: Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. Am J Physiol Gastrointest Liver Physiol 296: G823-G832, 2009
11. Stephen AM, Wiggins HS, Cummings JH: Effect of changing transit time on colonic microbial metabolism in man. Gut 28: 601-609, 1987
12. Khalif IL, Quigley EM, Konovitch EA, Maximova ID: Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 37: 838-849, 2005
13. Tanaka T, Doi K, Maeda-Mamiya R, Negishi K, Portilla D, Sugaya T, Fujita T, Noiri E: Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am J Pathol 174: 1203-1211, 2009
14. Vaziri ND: CKD impairs barrier function and alters microbial flora of the intestine: A major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 21: 587-592, 2012
15. Evenepoel P, Meijers BK, Bammens BR, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 114: S12-S19, 2009
16. Anders HJ, Andersen K, Stecher B: The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 83: 1010-1016, 2013
17. Declèves AE, Sharma K: Novel targets of antifibrotic and anti-inflammatory treatment in CKD. Nat Rev Nephrol 10: 257-267, 2014
18. Musch MW, Wang Y, Claud EC, Chang EB: Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota. Dig Dis Sci 58: 668-677, 2013
19. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G: Metab-olomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 106: 3698-3703, 2009
20. Niwa T: Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 20[Suppl]: S2-S6, 2010
21. Toyohara T, Suzuki T, Morimoto R, Akiyama Y, Souma T, Shiwaku HO, Takeuchi Y, Mishima E, Abe M, Tanemoto M, Masuda S, Kawano H, Maemura K, Nakayama M, Sato H, Mikkaichi T, Yamaguchi H, Fukui S, Fukumoto Y, Shimokawa H, Inui K, Terasaki T, Goto J, Ito S, Hishinuma T, Rubera I, Tauc M, Fujii-Kuriyama Y, Yabuuchi H, Moriyama Y, Soga T, Abe T: SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol 20: 2546-2555, 2009
22. Vaziri ND, Yuan J, Nazertehrani S, Ni Z, Liu S: Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 38: 99-103, 2013
23. Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S: Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrology (Carlton) 17: 733-738, 2012
24. Moeser AJ, Nighot PK, Roerig B, Ueno R, Blikslager AT: Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on muco-sal barrier repair in ischemic-injured porcine intestine. World J Gastroenterol 14: 6012-6017, 2008
25. De Lisle RC: Lubiprostone stimulates small intestinal mucin release. BMC Gastroenterol 12: 156, 2012
26. Vaziri ND, Yuan J, Norris K: Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 37: 1-6, 2013
27. Wong J, Piceno YM, Desantis TZ, Pahl M, Andersen GL, Vaziri ND: Expansion of urease-and uricase-containing, indole-and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal micro-biota in ESRD. Am J Nephrol 39: 230-237, 2014
28. Wang F, Zhang P, Jiang H, Cheng S: Gut bacterial translocation contributes to micro-inflammation in experimental uremia. Dig Dis Sci 57: 2856-2862, 2012
29. Wang IK, Lai HC, Yu CJ, Liang CC, Chang CT, Kuo HL, Yang YF, Lin CC, Lin HH, Liu YL, Chang YC, Wu YY, Chen CH, Li CY, Chuang FR, Huang CC, Lin CH, Lin HC: Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Appl Environ Mi-crobiol 78: 1107-1112, 2012
30. Kakino M, Izuta H, Ito T, Tsuruma K, Araki Y, Shimazawa M, Oyama M, Iinuma M, Hara H: Agarwood induced laxative effects via ace-tylcholine receptors on loperamide-induced constipation in mice. Biosci Biotechnol Bio-chem 74: 1550-1555, 2010
31. Kim SW, Suda W, Kim S, Oshima K, Fukuda S, Ohno H, Morita H, Hattori M: Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res 20: 241-253, 2013
32. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504: 446-450, 2013
33. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T: Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2: 488-494, 2003
34. Akiyama Y, Takeuchi Y, Kikuchi K, Mishima E, Yamamoto Y, Suzuki C, Toyohara T, Suzuki T, Hozawa A, Ito S, Soga T, Abe T: A metab-olomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spec-trometry (CE-MS). Toxins (Basel) 4: 1309-1322, 2012